Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolvaptan in ADPKD (POLY)
NCT03803124Phase 3Completed
- Sponsor
- Regionshospitalet Holstebro
- Start
- Dec 2015
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tolvaptan in autosomal dominant polycystic kidney disease (ADPKD), sponsored by Regionshospitalet Holstebro. Started Dec 2015; status: completed.
02
Drugs
tolvaptan
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT03803124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03803124.